JADE101 — Topline data
2027
• Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027Source filing
JBIO biotech catalysts & pipeline
JADE BIOSCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
JADE201 — Interim data
2027
Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027Source filing
JADE301 — Interim data
H2 2027
JADE301, a potentially best-in-class, half-life–extended anti-IFN-ß for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027Source filing
JADE301 — Conference presentation
Sep 30
Jade plans to present preclinical data further characterizing JADE301 at the 2026 European Academy of Dermatology and Venereology Congress, taking place September 30–October 3, 2026, in Vienna, Austria.Source filing